| Income Statement | 2025-09-30 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Product revenue, net | 3,290 | 2,822 | 2,208 | |
| Cost of revenue | 1,367 | 1,555 | 3,367 | |
| Asset impairment charges | - | - | 58,957 | |
| Research and development | 9,289 | 9,114 | 9,698 | |
| Selling, general and administrative | 25,701 | 7,707 | 7,502 | |
| Costs and expenses | 36,357 | 18,376 | 79,524 | |
| Operating loss | -33,067 | -15,554 | -77,316 | |
| Grant income | 982 | 1,668 | - | |
| Loss on extinguishment of debt | 0 | - | - | |
| Interest income | 1,231 | - | - | |
| Other expense, net | -1,156 | -327 | -605 | |
| Fair value - mark to market adjustment | - | - | 855 | |
| Net loss available to common stockholders | -32,010 | -14,213 | -78,776 | |
| Net loss per common share, basic | -3.59 | -0.23 | -19.28 | |
| Net loss per common share, diluted | -3.59 | -0.23 | -19.28 | |
| Weighted average common shares outstanding, basic | 8,922,792 | 62,122,283 | 4,085,132 | |
| Weighted average common shares outstanding, diluted | 8,922,792 | 62,122,283 | 4,085,132 | |
Tonix Pharmaceuticals Holding Corp. (TNXP)
Tonix Pharmaceuticals Holding Corp. (TNXP)